What are the risks of hepatotoxicity associated with rituximab and how should liver function be monitored and managed during therapy?

Rituximab and Liver Injury

Rituximab carries a significant risk of hepatitis B virus (HBV) reactivation that can result in fulminant hepatitis, hepatic failure, and death, but direct hepatotoxicity from rituximab itself is rare. The primary hepatic concern with rituximab is HBV reactivation, not intrinsic liver injury 1.

Understanding the Hepatic Risks

HBV Reactivation: The Critical Concern

Rituximab is classified as a high-risk agent for HBV reactivation due to its B-cell depleting mechanism 2, 3. The evidence demonstrates:

• HBsAg-positive patients: 50-64% reactivation risk without prophylaxis 4
• Resolved HBV infection (HBsAg-negative/anti-HBc-positive): 55% reactivation risk, with seroreversion rates of 20-40% 3, 4
• Rheumatic disease patients: 59% of HBsAg-positive patients experienced reactivation at median 14.6 months post-rituximab 4

The FDA has issued a black-box warning specifically for HBV reactivation with rituximab 1. This is not a theoretical risk—it results in fulminant hepatitis, hepatic failure, and death when not properly managed.

Direct Hepatotoxicity

Unlike the tuberculosis medications discussed in several provided guidelines [5-5], rituximab does not cause direct drug-induced liver injury in the traditional sense. The liver injury associated with rituximab is almost exclusively related to HBV reactivation.

Mandatory Screening Protocol

All patients must be screened for HBV before initiating rituximab 2, 1:

• HBsAg (hepatitis B surface antigen)
• Anti-HBc (hepatitis B core antibody)
• Consider anti-HBs (hepatitis B surface antibody) for complete assessment

Current data shows that only 46% of patients receive appropriate screening, with significant variation between academic (65%) and non-academic centers (32%) 6. This represents a critical gap in patient safety.

Antiviral Prophylaxis Strategy

For HBsAg-Positive Patients

Prophylactic antiviral therapy is strongly recommended and must be initiated before rituximab 7, 2:

• Start potent nucleos(t)ide analogues (NAs) such as entecavir or tenofovir
• With NA prophylaxis, no hepatitis flares occurred in one cohort 8
• Without prophylaxis, 59% experienced flare (24.5 per 100 person-years) and 8% developed liver decompensation 8

For HBsAg-Negative/Anti-HBc-Positive Patients (Resolved Infection)

Prophylactic antiviral therapy is strongly recommended for rituximab 7, 2, 3:

• Rituximab is the only agent where prophylaxis is strongly recommended even for resolved HBV infection
• The reactivation rate of 16.9% in this population is unacceptably high without prophylaxis 3
• B-cell depleting agents have the most potent and durable immunosuppressive effect 3

This recommendation differs from other immunosuppressants where monitoring alone may be acceptable for resolved HBV infection 2.

Duration of Antiviral Prophylaxis

Continue antiviral prophylaxis for at least 12 months after completing rituximab therapy 8, 9:

• HBV reactivation can occur up to 12 months (and beyond) after rituximab cessation 3
• Late reactivation occurred in 28.6% of cases in one series 9
• Stopping NAs within one year post-rituximab resulted in 38% flare rate even without rituximab retreatment 8
• The 1-year reactivation rate was 29-45% in HBsAg-positive patients and continued to increase beyond 2 years 4

Critical Caveat for Rituximab Retreatment

If rituximab retreatment is needed after NA discontinuation, the risk escalates dramatically 8:

• 75% flare rate with retreatment
• 63% liver decompensation rate
• This represents a medical emergency scenario

Monitoring Protocol During Therapy

For Patients on Antiviral Prophylaxis

Monitor liver function tests and HBV DNA levels periodically 10, 1:

• Baseline: CBC, hepatic and renal function before initiating rituximab
• During therapy: Daily monitoring during initiation, then interval testing based on clinical response
• HBV DNA monitoring: Assess levels before initiating rituximab; baseline HBV DNA ≥20 IU/mL predicts 10.9-fold increased reactivation risk 4

For Patients Without Known HBV Infection

Periodic monitoring of hepatic function is recommended 10:

• CBC and hepatic function should be monitored periodically during therapy
• Daily monitoring during initiation phase
• Subsequent intervals depend on clinical response

Management of HBV Reactivation

If HBV reactivation occurs, immediately discontinue rituximab and all concomitant immunosuppressive medications 1:

1. Start or optimize antiviral therapy immediately
2. Monitor liver function closely
3. Assess for signs of hepatic decompensation
4. Consider hepatology consultation

The mortality risk is real—one fatal liver decompensation was reported in a recent series 6.

Risk Factors for Reactivation

Higher baseline HBV DNA level (≥20 IU/mL vs <20 IU/mL) is an independent predictor 4:

• 10.9-fold increased risk of HBV reactivation (95% CI: 1.1-107)
• 14.8-fold increased risk of HBV-associated hepatitis (95% CI: 1.4-158)

Concurrent steroid use increases risk in a dose-dependent manner 8.

Common Pitfalls to Avoid

1. Failing to screen: Nearly half of patients are not properly screened 6
2. Inadequate prophylaxis duration: Stopping NAs too early leads to high flare rates 8, 9
3. Assuming resolved HBV is safe: The 55% reactivation rate proves otherwise 4
4. Retreating without restarting prophylaxis: This leads to 75% flare rate and 63% decompensation 8
5. Monitoring for less than 12 months: Late reactivation is common 3, 9

Special Consideration: Autoimmune Hepatitis

Rituximab has been used successfully to treat refractory autoimmune hepatitis itself 11, 12, achieving complete remission in 55% of patients. However, this does not change the HBV screening and prophylaxis requirements—these protocols remain mandatory regardless of the indication for rituximab.